{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:52:24Z","timestamp":1760061144634,"version":"build-2065373602"},"reference-count":9,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2006,6,23]],"date-time":"2006-06-23T00:00:00Z","timestamp":1151020800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedical Chromatography"],"published-print":{"date-parts":[[2006,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Tipranavir is the most recently introduced protease inhibitor for the suppression of the human immunodeficiency virus (HIV). A selective reversed\u2010phase liquid chromatographic assay, previously developed for atazanavir, has been extended and validated for tipranavir in plasma. Compounds were isolated from a 500 \u00b5L plasma sample using liquid\u2013liquid extraction with dichloromethane. After evaporation and reconstitution of the extract the sample was analysed using reversed\u2010phase liquid chromatography and ultra violet detection at 280 nm. In the evaluated concentration range (0.2\u201350 \u00b5g\/mL tipranavir), intra\u2010day precisions were \u22648% and inter\u2010day precisions were \u226410%. Accuracies between 95 and 108% were found. The clinical applicability of the assay was demonstrated in an HIV\u2010infected patient who ingested 500 mg tipranavir bid in combination with 100 mg ritonavir. Copyright \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/bmc.667","type":"journal-article","created":{"date-parts":[[2006,6,27]],"date-time":"2006-06-27T07:07:31Z","timestamp":1151392051000},"page":"671-673","source":"Crossref","is-referenced-by-count":1,"title":["Liquid chromatographic assay for the non\u2010peptidic protease inhibitor tipranavir in plasma"],"prefix":"10.1002","volume":"20","author":[{"given":"Rolf W.","family":"Sparidans","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frits","family":"Dost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristel M. L.","family":"Crommentuyn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan H. M.","family":"Schellens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos H.","family":"Beijnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,23]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"615","article-title":"Tipranavir gets approved","volume":"19","author":"Anonymous","year":"2005","journal-title":"AIDS Patient Care STDS"},{"key":"e_1_2_1_3_1","unstructured":"Center for Drug Evaluation and Research of the US Department of Health and Human Services Food and Drug Administration. Guidance for industry; Bioanalytical method validation. Available at:www.fda.gov\/cder\/guidance\/4252fnl.htm 2001 (accessed 30 November 2004)."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.11.040"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2004.01.041"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200565120-00005"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1907"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2005.10.024"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1081\/JLC-100101455"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bmc.530"}],"container-title":["Biomedical Chromatography"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbmc.667","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bmc.667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:54:12Z","timestamp":1760043252000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/bmc.667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6,23]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2006,8]]}},"alternative-id":["10.1002\/bmc.667"],"URL":"https:\/\/doi.org\/10.1002\/bmc.667","archive":["Portico"],"relation":{},"ISSN":["0269-3879","1099-0801"],"issn-type":[{"type":"print","value":"0269-3879"},{"type":"electronic","value":"1099-0801"}],"subject":[],"published":{"date-parts":[[2006,6,23]]}}}